Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
50.96
-0.32 (-0.62%)
At close: Apr 10, 2026, 4:00 PM EDT
51.05
+0.09 (0.18%)
After-hours: Apr 10, 2026, 7:31 PM EDT
Moderna Revenue
In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%. Moderna had revenue of $678.00M in the quarter ending December 31, 2025, a decrease of -29.81%.
Revenue (ttm)
$1.94B
Revenue Growth
-39.93%
P/S Ratio
10.40
Revenue / Employee
$413,617
Employees
4,700
Market Cap
20.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
| BridgeBio Pharma | 502.08M |
MRNA News
- 4 days ago - Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 - Accesswire
- 4 weeks ago - What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Benzinga
- 5 weeks ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 5 weeks ago - Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang - Reuters
- 5 weeks ago - Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
- 5 weeks ago - Moderna Stock Rallies. This Big Risk Just Got Eliminated. - Barrons
- 5 weeks ago - Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline - Market Watch
- 5 weeks ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ